(NASDAQ: DNLI) Denali Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Denali Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast DNLI's revenue for 2025 to be $6,223,671,825, with the lowest DNLI revenue forecast at $2,193,184,170, and the highest DNLI revenue forecast at $10,965,920,850. On average, 12 Wall Street analysts forecast DNLI's revenue for 2026 to be $14,699,597,581, with the lowest DNLI revenue forecast at $1,397,789,378, and the highest DNLI revenue forecast at $40,743,513,387.
In 2027, DNLI is forecast to generate $32,520,973,510 in revenue, with the lowest revenue forecast at $13,646,869,179 and the highest revenue forecast at $66,857,026,238.